MannKind (MNKD) Misses Q3 EPS by 11c

MannKind (NASDAQ: MNKD) reported Q3 EPS of ($0.31), $0.11 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $2 million versus the consensus estimate of $3.88 million.

• Afrezza net revenue grew 28% and 246% vs. 2Q 2017 and 3Q 2016, respectively
• Cash burn of $23.3 million in 3Q 2017
• Exchanged all outstanding Series A and B Common Stock Warrants for an aggregate of 1.3 million shares of the Company’s common stock
• FDA approved label changes for Afrezza

For earnings history and earnings-related data on MannKind (MNKD) click here.

You May Also Be Interested In

• MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
• Amylyx ALS drug shows no serious adverse events in Phase 1 trial
• BofA lists top 5 themes driving next $1tn in incremental semi sales